AarogyaAI Founders | Image Credits: AarogyaAI

AarogyaAI, an AI-enabled healthtech SaaS startup, has raised USD 700K (INR 5.2 crore approx.) in a seed funding round from Info Edge (India) backed Redstart Labs and Avaana Capital on 7 January 2022.

Investors: The latest funding round drew participation from Info Edge (India) backed Redstart Labs and Avaana Capital. In addition, existing investors including, Entrepreneur First and First In Ventures, also contributed to the round.

The Objectives behind the funding: The company plans to deploy the current proceeds for Research & Development, team expansion, validation, and pilot deployments, said Co-founder and CEO Praapti Jayaswal. 

About AarogyaAI

Image Credits: AarogyaAI

Founded in 2019 by Praapti Jayaswal and Avlokita Tiwari, AarogyaAI has built an AI-enabled SaaS platform where the  DNA sequence from the bacteria infecting a patient can be uploaded, which is then analysed using a machine learning algorithm and AI to generate a report showing the patient’s comprehensive drug susceptibility status. 

This includes a list of drugs and their combinations that will and will not work for the patient. Doctors can then use the report to prescribe a more potent combination of antibiotics, significantly bringing down the duration of the treatment to less than six months. Its software has been validated internally and has reached its external validation and pilot testing stage. 

It is anticipated to be rolled out for commercial use by mid-2022. The startup aims to scale pan-India through five to seven public and three to four private chains by 2022 and expand to other countries that are grappling with TB.

What the Founder has to say:

“Experts believe that superbugs will cause the next pandemic, and we need to start staying ahead in this game with pathogens, rather than playing catch up. It’s time we exploit cutting-edge technologies, translate years of research to apply in the real world. We need a way to predict the nature of these pathogens and make predictions and drugs that can cut them off before the harm they do,” said Co-founder and Chief Executive Officer (CEO), Praapti Jayaswal.

What the Investor has to say:

“Genome sequencing is now at the heart of discovering drugs, ascertaining their efficacy and finding more about sickness than ever. AarogyaAI team has taken up the challenge to solve for an extremely crucial aspect of treating one the most ancient diseases. This would enable them to lay down the foundations for creating a platform that would hopefully help in several areas in research as well as clinical care,” said Vibhore Sharma, Partner, Redstart Labs.

For more extensive analysis and Market Intelligence reports feel free to approach us or visit our website: Venture Capital Market Intelligence Reports | VCBay.

We try our best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know

-if there are any discrepancies in any of our published stories,

-how we can improve,

-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback and thank you for stopping by!

Next Article

Previous articleUS-based biotech startup Ambagon Therapeutics raises USD 85 million in Series A round
Next articleUS-based SaaS startup Cion Digital raises USD 12 million in seed round
Manish writes about the startup ecosystem on VCBay. He is pursuing Master of Commerce from Delhi School of Economics, University of Delhi, and is passionate about the world of finance, information technology & entrepreneurship.



Please enter your comment!
Please enter your name here